Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1971 1
1984 1
1994 1
1996 1
1999 2
2000 2
2001 2
2002 1
2003 2
2004 5
2005 4
2006 7
2007 5
2008 3
2009 8
2010 4
2011 5
2012 2
2013 12
2014 12
2015 8
2016 8
2017 16
2018 17
2019 11
2020 19
2021 11
2022 12
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup. Fornecker LM, et al. Among authors: pascal l. J Clin Oncol. 2023 Jan 10;41(2):327-335. doi: 10.1200/JCO.21.01281. Epub 2022 Jul 22. J Clin Oncol. 2023. PMID: 35867960 Free article. Clinical Trial.
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
Mekinian A, Zhao LP, Chevret S, Desseaux K, Pascal L, Comont T, Maria A, Peterlin P, Terriou L, D'Aveni Piney M, Gourin MP, Vey N, Rauzy OB, Grobost V, Bezanahary H, Dimicoli-Salazar S, Banos A, Wickenhauser S, De Renzis B, Durot E, Natarajan-Amé S, Voillat L, Chermat F, Lemaire K, Jachiet V, Himberlin C, Thépot S, Diaz JMT, Frenzel L, Gyan E, Denis G, Hirsch P, Kosmider O, Ades L, Fain O, Fenaux P. Mekinian A, et al. Among authors: pascal l. Leukemia. 2022 Nov;36(11):2739-2742. doi: 10.1038/s41375-022-01698-8. Epub 2022 Sep 14. Leukemia. 2022. PMID: 36104395 Clinical Trial. No abstract available.
Bortezomib and Waldenstrom's macroglobulinemia.
Pascal L, Gay J, Willekens C, Wemeau M, Balkaran S, Robu D, Roccaro A, Morel P, Ghobrial I, Leleu X. Pascal L, et al. Expert Opin Pharmacother. 2009 Apr;10(5):909-16. doi: 10.1517/14656560902800160. Expert Opin Pharmacother. 2009. PMID: 19351237 Review.
SlicerSALT: Shape AnaLysis Toolbox.
Vicory J, Pascal L, Hernandez P, Fishbaugh J, Prieto J, Mostapha M, Huang C, Shah H, Hong J, Liu Z, Michoud L, Fillion-Robin JC, Gerig G, Zhu H, Pizer SM, Styner M, Paniagua B. Vicory J, et al. Among authors: pascal l. Shape Med Imaging (2018). 2018 Sep;11167:65-72. doi: 10.1007/978-3-030-04747-4_6. Epub 2018 Nov 23. Shape Med Imaging (2018). 2018. PMID: 31032495 Free PMC article.
Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series.
Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, Huart A, Javaugue V, Pascal L, Royer B, Talbot A, Gounot R, Hegenbart U, Schonland S, Karlin L, Harel S, Kastritis E, Bridoux F, Jaccard A, Arnulf B. Forgeard N, et al. Among authors: pascal l. Blood. 2024 Feb 22;143(8):734-737. doi: 10.1182/blood.2023022937. Blood. 2024. PMID: 38096365 No abstract available.
Tipping point arises earlier under a multiple-stressor scenario.
Carrier-Belleau C, Pascal L, Tiegs SD, Nozais C, Archambault P. Carrier-Belleau C, et al. Among authors: pascal l. Sci Rep. 2023 Oct 5;13(1):16780. doi: 10.1038/s41598-023-44012-x. Sci Rep. 2023. PMID: 37798389 Free PMC article.
171 results